although
contribut
genet
complex
cardiovascular
diseas
atherosclerosi
accept
quit
time
full
detail
knowledg
individu
caus
gene
elus
advent
genom
technolog
method
necessari
tool
avail
begin
pinpoint
gene
contribut
diseas
suscept
progress
one
approach
appli
extens
candid
gene
discoveri
gene
express
analysi
human
anim
tissu
use
microarray
gene
identifi
genom
studi
provid
valuabl
insight
diseas
biolog
repres
initi
step
toward
develop
diagnost
test
therapeut
strategi
substanti
improv
human
health
paper
highlight
progress
made
use
gene
express
analysi
cardiovascular
genom
research
potenti
appli
find
clinic
medicin
announc
herald
start
new
era
medic
scienc
genom
data
markedli
improv
abil
diagnos
treat
heart
diseas
cancer
myriad
chronic
diseas
understand
relev
individu
genom
profil
molecular
fingerprint
diseas
context
might
help
us
gain
valuabl
insight
diseas
mechan
could
foundat
tailor
health
care
individu
patient
basi
predict
diseas
cours
respons
therapi
opportun
also
exist
replac
diagnost
test
current
invas
natur
genom
test
perform
without
detect
risk
signific
stress
patient
object
articl
provid
overview
state
genom
research
cardiovascular
medicin
specif
regard
use
microarray
technolog
function
genom
common
cardiovascular
diseas
atherosclerosi
atrial
fibril
heart
failur
affect
million
american
cost
health
care
system
billion
dollar
manner
clinician
diagnos
treat
diseas
must
chang
consid
diseas
progress
seri
distinct
state
goal
clinician
stabil
patient
within
diseas
state
reduc
probabl
progress
next
often
wors
state
moreov
mani
current
therapi
given
state
deriv
larg
prospect
studi
prism
platelet
receptor
inhibit
ischem
syndrom
manag
cure
clopidogrel
unstabl
angina
prevent
recurr
event
trial
subject
treatment
control
group
studi
process
random
ostens
consid
ident
although
might
statist
signific
overal
treatment
effect
imposs
know
whether
treatment
regimen
effect
specif
individu
case
point
stateoftheart
treatment
acut
coronari
syndrom
use
cocktail
drug
everi
patient
present
identifi
medic
combin
medic
provid
optim
benefittorisk
ratio
individu
patient
thu
patient
diseas
state
otherwis
ident
respect
measur
variabl
demograph
laboratori
valu
comorbid
might
mark
differ
clinic
cours
respect
tempo
intens
diseas
develop
therapeut
respons
greatest
limit
optim
therapeut
strategi
individu
patient
incomplet
understand
diseas
biolog
inabl
differenti
individu
accord
rel
diseas
risk
inher
genet
makeup
individu
like
play
larg
role
determin
clinic
cours
modul
respons
risk
factor
smoke
cholesterol
obes
exampl
intrins
capac
arteri
cardiac
repair
might
genet
determin
play
domin
role
rel
eventu
impact
cardiovascular
injuri
identifi
gene
gene
variant
determin
individu
diseas
suscept
might
abl
design
health
care
plan
identifi
patient
preclin
stage
diseas
also
allow
individu
therapi
efficaci
least
like
caus
side
effect
pregenom
era
opportun
identifi
relev
set
caus
gene
multigen
diseas
atherosclerosi
cardiomyopathi
limit
tradit
genet
approach
design
find
singl
loci
gene
power
caus
mendelian
cardiovascular
disord
prototyp
famili
hypercholesterolemia
type
disord
result
singl
base
chang
deoxyribonucl
acid
dna
lead
signific
chang
protein
abund
function
howev
common
gardenvarieti
disord
atherosclerosi
arteryspecif
inflammatori
process
like
result
multipl
gene
variant
interact
modul
individu
respons
clinic
risk
factor
smoke
serum
lipid
hypertens
gene
variant
usual
take
form
singl
base
chang
dna
singl
nucleotid
polymorph
snp
caus
modest
moder
chang
result
translat
protein
either
concentr
function
combin
howev
concurr
presenc
number
snp
within
specif
mix
risk
factor
determin
individu
suscept
diseas
develop
progress
small
contribut
snp
diseas
make
difficult
detect
tradit
genet
associ
studi
obviou
critic
challeng
identifi
gene
collect
contribut
multigen
disord
atherosclerosi
cardiomyopathi
advent
broadbas
genom
technolog
one
approach
emerg
real
opportun
perform
gene
express
analysi
diseaserelev
tissu
look
chang
abund
transcrib
gene
messeng
ribonucl
acid
mrna
correl
particular
diseas
state
clinic
outcom
therapeut
respons
although
dna
defin
person
inher
genet
make
activ
transcript
dna
rna
integr
individu
dynam
interact
environ
therefor
genom
studi
provid
us
opportun
identifi
gene
whose
rel
rna
abund
chang
differ
biolog
condit
premis
alter
express
respons
highlight
culprit
diseas
process
numer
way
measur
rna
abund
includ
northern
blot
multiplex
real
time
polymeras
chain
reaction
howev
techniqu
quantit
express
level
order
gene
time
recent
genom
technolog
dna
microarray
provid
us
opportun
assay
thousand
gene
simultan
give
us
unpreced
opportun
survey
genom
contribut
cardiovascular
diseas
microarray
refer
solid
substrat
glass
plastic
silicon
contain
thousand
microscop
print
spot
dna
fig
dna
spot
consist
hundr
thousand
ident
short
piec
dna
also
call
probe
appos
solid
materi
probe
uniqu
sequenc
nucleotid
base
pair
complementari
uniqu
singl
gene
microarray
experi
today
use
gene
chip
entir
complement
human
genom
repres
typic
microarray
experi
rna
extract
tissu
sampl
interest
mrna
fraction
rna
popul
repres
transcrib
gene
amplifi
fluoresc
tag
attach
molecul
entir
pool
incub
microarray
tag
mrna
molecul
hybrid
probe
contain
specif
complementari
sequenc
via
base
pair
complementari
mrna
bind
probe
array
hybrid
microarray
place
scanner
laser
direct
onto
spot
caus
tag
fluoresc
result
fluoresc
intens
proport
number
tag
rna
hybrid
probe
spot
therefor
measur
intens
repres
activ
express
level
gene
consequ
genom
profil
gener
particular
tissu
stage
health
diseas
util
gene
signatur
gener
speak
twofold
initi
step
identifi
diseaseassoci
gene
candid
gene
diseas
observ
studi
dna
deoxyribonucl
acid
icm
ischem
cardiomyopathi
lvad
left
ventricular
assist
devic
mrna
messeng
ribonucl
acid
nf
nonfail
myocardi
sampl
nicm
nonischem
cardiomyopathi
pmbc
peripher
blood
mononuclear
cell
qtl
quantit
trait
locu
snp
singl
nucleotid
polymorph
biomark
first
instanc
gene
compris
genom
signatur
definit
diseaseassoci
thu
candid
look
snp
associ
diseas
suscept
particular
treatment
outcom
identifi
potenti
panel
diseas
snp
could
screen
patient
dna
via
blood
test
presenc
gene
variant
aid
diagnosi
plan
treatment
certainli
candid
gene
might
substanti
improv
understand
diseas
biolog
subsequ
lead
identif
potenti
target
new
treatment
strategi
potenti
use
genom
inform
use
gene
signatur
directli
diseas
biomark
gene
express
data
appropri
set
extraordinarili
detail
patient
phenotyp
could
use
accur
stratifi
patient
popul
diseas
risk
respons
therapi
case
genom
data
repres
mean
distinguish
patient
otherwis
ident
tradit
clinic
variabl
although
still
work
progress
cardiovascular
medicin
look
field
oncolog
see
futur
lie
clinic
use
genom
advanc
rapidli
area
oncolog
owe
part
inher
advantag
abl
directli
assay
tumor
cancer
literatur
provid
us
guidanc
gene
express
data
might
appli
context
cardiovascular
medicin
predomin
role
cancer
genom
riskstratifi
patient
classifi
tradit
clinic
factor
greater
granular
initi
diagnosi
clinic
stage
gene
express
profil
tumor
use
predict
longterm
diseas
recurr
surviv
well
possibl
plan
treatment
regimen
concret
exampl
patient
high
risk
breast
cancer
recurr
identifi
even
earli
stage
diseas
two
test
commerci
avail
us
patient
earli
invas
breast
cancer
test
design
complement
diagnost
armamentarium
avail
clinician
select
appropri
therapeut
strategi
patient
earlystag
breast
cancer
popul
patient
tradit
undergo
surgic
resect
follow
radiat
treatment
hormon
adjuv
therapi
new
genom
assay
seek
identifi
individu
significantli
higher
risk
recurr
potenti
warrant
aggress
treatment
strategi
chemotherapi
spite
rather
good
prognosi
indic
tradit
risk
profil
integr
molecular
characterist
patient
tumor
clinic
demograph
data
allow
addit
granular
clinic
decisionmak
genom
research
progress
slowli
cardiovascular
field
owe
inabl
access
enough
inform
tissu
perhap
reason
much
effort
gone
look
diseas
snp
studi
test
use
blood
dna
sampl
still
within
past
year
landmark
studi
use
human
aortic
atrial
ventricular
tissu
improv
understand
diseas
biolog
translat
applic
might
improv
abil
make
clinic
decis
also
becom
evid
blood
cell
also
provid
usabl
genom
inform
cardiovascular
condit
turn
attent
recent
signific
research
area
cardiovascular
genom
atherosclerosi
given
extraordinarili
heavi
health
burden
atherosclerosi
thromboembol
complic
condit
one
first
foci
appli
genom
technolog
avail
rel
lack
appropri
human
target
tissu
recent
critic
limit
factor
recent
studi
investig
perform
gene
express
analysi
exclus
human
aortic
tissu
identifi
gene
predict
extent
atherosclerot
burden
aorta
tissu
collect
time
organ
harvest
heart
lung
donor
preserv
maintain
premortem
rna
integr
inher
symmetri
diseas
develop
longitudin
midlin
thorac
aorta
allow
quantit
analysi
atherosclerosi
onehalf
specimen
perform
gene
express
profil
half
seemingli
palindrom
charact
diseas
mosaic
allow
direct
associ
gene
express
profil
diseas
burden
phenotyp
gene
express
data
use
develop
predict
model
accur
classifi
unknown
aorta
minim
sever
diseas
accuraci
predict
capabl
gene
impli
potenti
biolog
relev
gene
provid
predict
capabl
includ
mani
previous
associ
atherosclerosi
well
entir
novel
set
gene
never
link
cardiovascular
disord
also
larg
number
gene
whose
role
atherosclerosi
gone
unrecogn
given
challeng
obtain
human
arteri
tissu
studi
atherosclerosi
anim
model
invalu
tool
determin
mechan
underli
diseas
progress
influenc
diet
environment
factor
expresss
apolipoprotein
e
knock
apo
wellestablish
diseas
model
atherosclerosi
use
year
great
relev
human
diseas
model
allow
studi
atherosclerot
inflamm
control
number
import
clinic
variabl
age
gender
diet
genet
homogen
background
recent
studi
gene
express
analys
use
aorta
apo
mice
differ
age
diet
defin
genom
signatur
diseas
burden
could
differenti
differ
mous
atherosclerot
diseas
state
genom
model
test
human
diseas
profil
gene
mrna
atherectomi
sampl
extract
atherosclerot
lesion
instent
restenot
lesion
find
mous
genom
signatur
could
clearli
differenti
atherosclerot
restenot
lesion
high
degre
accuraci
thu
valid
human
genom
predictor
discov
mous
import
suggest
genom
data
deriv
across
speci
might
applic
human
disord
similar
gene
express
analysi
mous
atherosclerosi
model
show
similar
find
regard
genom
signatur
indic
differ
diseas
state
genom
signatur
mous
tissu
homolog
seen
human
tissu
studi
also
went
demonstr
presenc
molecular
repair
signal
mous
aorta
implic
role
bone
marrowderiv
progenitor
cell
balanc
vascular
damag
restor
one
first
instanc
chronic
diseas
progress
directli
link
chang
bodi
abil
repair
therefor
studi
implic
seri
gene
program
diseas
progress
also
demonstr
gene
express
analysi
implic
specif
diseas
mechan
result
studi
current
direct
diagnost
util
reli
avail
diseas
tissu
howev
inform
contain
gene
express
signatur
ie
gene
make
gene
express
pattern
differenti
one
diseas
state
anoth
serv
basi
candid
gene
identif
use
genet
associ
studi
although
whole
genom
scan
associ
studi
like
supersed
candid
gene
approach
candid
gene
identifi
gene
express
signatur
also
use
facilit
whole
genom
scan
priorit
target
within
chromosom
region
contrast
tradit
method
identifi
candid
establish
role
biolog
diseas
gene
express
repres
novel
nonbias
methodolog
thu
gene
identifi
genom
studi
use
basi
genet
associ
studi
gene
might
identifi
new
biolog
relev
diseas
process
key
challeng
remain
identifi
gene
gene
caus
function
relev
clinic
relev
applic
genom
technolog
cardiovascular
medicin
would
pointofcar
assay
diagnost
simpl
bloodbas
test
evid
suggest
might
real
possibl
peripher
blood
mononuclear
cell
pmbc
play
critic
role
inflammatori
pathway
lead
atherosclerosi
constitut
major
cellular
compon
atherosclerot
lesion
repair
therefor
gene
express
profil
pbmc
could
potenti
yield
diagnost
signatur
atherosclerosi
one
earliest
studi
perform
small
group
patient
without
signific
coronari
arteri
diseas
four
case
three
control
subject
rna
extract
pbmc
patient
investig
evalu
rel
abund
transcript
found
gene
significantli
upregul
downregul
patient
coronari
diseas
compar
normal
control
subject
although
small
studi
point
feasibl
use
gene
express
profil
blood
detect
coronari
heart
diseas
anoth
recent
studi
also
provid
addit
evid
blood
gene
express
profil
might
util
detect
atherosclerosi
investig
perform
gene
express
analysi
pbmc
find
gene
differenti
express
patient
carotid
atherosclerosi
gene
express
signatur
patient
sever
carotid
atherosclerosi
necessit
surgic
intervent
compar
control
cohort
without
measur
diseas
investig
found
number
regulatori
gene
transcript
factor
includ
finkelbiskisjinkin
osteosarcoma
protooncogen
dual
specif
nuclear
factor
kappa
light
polypeptid
gene
enhanc
bcell
inhibitoralpha
significantli
alter
patient
sever
carotid
diseas
given
sampl
size
use
studi
meant
exploratori
analysi
identifi
differenti
express
gene
improv
biolog
insight
atherosclerosi
pbmc
report
cell
valid
use
diagnost
prognost
tool
howev
provid
proof
concept
bloodbas
gene
express
data
seem
inform
individu
overal
inflammatori
state
possibl
specif
inform
relev
carotid
atherosclerosi
identifi
gene
might
repres
gene
whose
variant
might
contribut
patholog
enhanc
inflammatori
respons
endotheli
damag
high
serum
cholesterol
hypertens
one
first
studi
show
assay
pbmc
potenti
inform
diagnost
context
presenc
absenc
atherosclerosi
human
one
could
envis
genom
profil
pbmc
could
serv
adjunct
test
noninvas
function
studi
improv
sensit
specif
presenc
absenc
sever
diseas
import
consider
whether
carotid
atherosclerosi
associ
gene
express
profil
distinct
associ
coronari
aortic
lower
extrem
vascular
diseas
cardiac
transplant
signific
progress
made
applic
genom
inform
predict
risk
acut
reject
patient
undergon
cardiac
transplant
one
studi
research
profil
pbmc
cohort
cardiac
transplant
patient
found
pattern
gene
express
statist
associ
reject
studi
longitudin
clinic
data
blood
sampl
collect
time
surveil
right
heart
biopsi
period
right
heart
biopsi
standard
care
assess
sign
acut
reject
often
clinic
manifest
analysi
gene
express
data
pbmc
collect
transplant
patient
show
differenti
express
gene
predict
develop
acut
reject
defin
histolog
diagnosi
blood
serum
assay
addit
patient
experienc
reject
major
discriminatori
gene
return
baselin
level
express
treatment
immun
reject
episod
result
support
util
gene
express
diagnosi
also
potenti
use
genom
data
measur
respons
treatment
similar
studi
design
anoth
research
group
also
found
gene
pbmc
predict
acut
reject
cardiac
transplant
patient
find
led
develop
commerci
avail
bloodbas
test
detect
acut
cardiac
reject
investig
examin
data
transplant
recipi
multiinstitut
cargo
cardiac
allograft
reject
gene
express
observ
studi
cargo
studi
investig
collect
longitudin
clinic
data
blood
sampl
time
surveil
right
heart
biopsi
analysi
gene
express
data
pbmc
identifi
core
group
gene
differenti
express
patient
variou
stage
acut
reject
inform
bloodbas
test
develop
assign
risk
develop
reject
within
next
month
neg
predict
valu
therefor
pure
basi
gene
express
data
peripher
blood
test
might
allow
patient
forego
risk
albeit
minim
surveil
right
heart
biopsi
result
neg
studi
also
shown
genom
data
might
inform
level
immunosuppress
requir
individu
patient
particularli
whether
receiv
effect
dose
corticosteroid
independ
actual
dose
exampl
patient
receiv
mg
prednison
might
gene
express
profil
typic
patient
receiv
dose
indic
gene
express
profil
might
accur
pharmacodynam
biomark
dose
find
tradit
method
although
data
need
substanti
find
repres
opportun
earli
applic
pharmacogenom
assist
drug
titrat
one
issu
type
studi
sensit
test
predict
clinic
outcom
abil
thoroughli
assess
accur
reproduc
phenotyp
absolut
necess
use
gene
express
drive
decisionmak
cargo
studi
phenotyp
associ
gene
express
histolog
grade
reject
determin
panel
clinician
substanti
variabl
grade
reject
myocardi
sampl
affect
consequ
reliabl
assay
predict
reject
applic
genom
clinic
practic
develop
accuraci
measur
phenotyp
crucial
event
gene
expressionbas
assay
transplant
reject
repres
first
substanti
clinic
relev
applic
genom
field
cardiovascular
medicin
electrophysiologyatri
fibril
field
electrophysiolog
provid
tremend
opportun
genom
data
guid
clinic
decisionmak
new
devicebas
therapeut
strategi
develop
unmatch
benefit
patient
need
also
come
substanti
side
effect
particularli
appli
patient
need
least
furthermor
becom
increasingli
evid
arrhythmia
result
combin
effect
myocardi
degener
age
smaller
extent
channelopathi
genet
variat
ion
channel
individu
effect
influenc
genet
factor
lead
abnorm
rhythm
howev
genet
factor
combin
interact
arrhythmia
might
develop
context
first
applic
microarray
technolog
improv
understand
biolog
arrhythmia
particular
atrial
fibril
two
group
recent
publish
result
function
genom
studi
use
human
tissu
studi
use
right
atrial
appendag
obtain
time
coronari
arteri
bypass
surgeri
valv
repair
surgeri
gene
express
profil
assay
one
studi
evalu
known
gene
dna
microarray
found
gene
differenti
express
atrial
fibril
sampl
rel
control
sampl
normal
sinu
rhythm
within
predict
gene
express
signatur
preponder
gene
relat
reactiv
oxygen
speci
enzym
modul
respons
oxid
stress
led
specul
oxid
damag
perhap
inflammatori
pathway
could
one
initi
atrial
fibril
well
potenti
condit
studi
use
rel
limit
gene
set
current
standard
one
first
broad
nonbias
investig
molecular
chang
human
atrial
fibril
anoth
similar
investig
also
use
atrial
tissu
sampl
taken
time
cardiac
surgeri
find
gene
associ
presenc
chronic
atrial
fibril
assay
larger
set
gene
patient
atrial
fibril
compar
individu
normal
sinu
rhythm
investig
found
differenti
express
gene
relat
remodel
contractil
protein
ion
channel
chang
addit
chang
express
gene
relat
metabol
observ
might
indic
higher
energi
need
fibril
state
studi
sought
improv
biolog
insight
atrial
fibril
studi
atherosclerosi
neither
meant
yield
data
could
use
directli
diagnost
priorit
gene
help
suggest
possibl
mechan
might
contribut
develop
atrial
fibril
obvious
abil
jacc
vol
seo
et
al
juli
gene
express
analysi
cardiovascular
diseas
studi
readili
access
tissu
would
ideal
clinic
genom
point
difficult
say
whether
possibl
like
construct
clinic
test
assess
genet
polymorph
might
indic
suscept
develop
arrhythmia
respons
pharmacolog
therapi
hypertens
although
hypertens
extraordinarili
import
cardiovascular
medicin
genom
studi
human
difficult
given
lack
access
tissu
much
know
molecular
mechan
contribut
hypertens
develop
anim
model
search
hypertens
candid
gene
anim
model
one
techniqu
use
extens
identif
quantit
trait
loci
qtl
qtl
portion
chromosom
highli
associ
trait
high
blood
pressur
one
problem
qtl
might
consist
hundr
gene
emerg
microarray
technolog
provid
method
priorit
gene
within
qtl
might
warrant
studi
strategi
known
genom
converg
investig
combin
gene
list
deriv
qtl
map
gene
express
analysi
diseaserelev
tissu
find
overlap
member
gene
identifi
interfac
two
dispar
approach
might
therefor
repres
particularli
intrigu
candid
gene
one
studi
illustr
approach
use
sabra
rat
hypertens
model
salt
suscept
independ
qtl
analysi
perform
show
two
loci
chromosom
rat
genom
highli
associ
hypertens
phenotyp
one
locu
span
centimorgan
shown
contain
known
gene
wherea
span
centimorgan
gene
gene
express
profil
gener
rat
kidney
felt
organ
intim
involv
sodium
balanc
research
found
seven
gene
overlap
qtl
gene
express
analys
although
anim
studi
repres
power
approach
studi
human
diseas
biolog
inform
tissu
readili
avail
polymorph
gene
identifi
studi
use
human
genet
associ
studi
heart
failur
heart
failur
fastestgrow
cardiovascular
diseas
recent
new
devic
therapi
biventricular
resynchron
automat
defibril
expand
armamentarium
strategi
treat
patient
heart
failur
patient
heart
failur
also
receiv
complex
medic
regimen
heterogen
clinic
cours
common
cardiovascular
diseas
genom
analys
might
play
substanti
role
improv
diagnost
health
care
plan
avail
human
tissu
obtain
time
transplant
placement
left
ventricular
assist
devic
lvad
facilit
use
microarray
analys
studi
cardiomyopathi
first
group
recent
genom
studi
sought
differenti
ischem
nonischem
cardiomyopathi
recent
studi
examin
number
myocardi
sampl
look
gene
express
differ
end
stage
ischem
nonischem
subtyp
also
attempt
develop
genom
profil
intermedi
clinic
phenotyp
studi
tissu
obtain
time
diagnost
biopsi
lvad
placement
larger
studi
examin
nearli
myocardi
sampl
two
differ
institut
obtain
time
transplant
explant
lvad
placement
biopsi
furthermor
sampl
repres
rang
clinic
diseas
stage
new
diagnosi
endstag
diseas
requir
transplant
research
demonstr
abil
differenti
patient
ischem
nonischem
cardiomyopathi
among
endstag
patient
remark
accuraci
howev
predict
accuraci
classifi
sampl
ischem
nonischem
drop
substanti
lvad
newli
diagnos
cohort
instruct
age
gender
hemodynam
differ
patient
cohort
add
power
predict
model
use
studi
overal
studi
demonstr
potenti
clinic
applic
classifi
patient
cardiomyopathi
subtyp
use
genom
phenotyp
gene
differenti
group
studi
might
provid
clue
treatment
regimen
could
tailor
specif
subtyp
final
although
describ
specif
gene
differenti
differ
cardiomyopathi
subtyp
time
aid
target
therapi
depend
upon
stage
natur
histori
diseas
process
well
track
respons
therapi
group
investig
also
perform
addit
analys
sampl
cohort
identifi
differenti
express
gene
without
assess
predict
capabl
reason
addit
analys
author
assert
candid
gene
aris
predict
model
although
instruct
truli
indic
diseas
biolog
rather
repres
stabl
express
profil
particular
diseas
set
although
still
unresolv
issu
nevertheless
provid
detail
analysi
gene
express
differ
patient
ischem
nonischem
cardiomyopathi
nonischem
cardiomyopathi
nicm
sampl
ischem
cardiomyopathi
icm
sampl
nonfail
nf
myocardi
sampl
gene
found
significantli
differenti
express
nicm
compar
nf
heart
gene
compar
icm
nf
heart
gene
overlap
across
two
comparison
repres
biolog
process
relev
cell
growth
signal
transduct
gene
uniqu
nicm
relat
metabol
uniqu
icm
seem
relat
catalyt
activ
angiotensinconvert
upregul
nicm
icm
sampl
point
potenti
differ
pharmacolog
target
patient
two
entiti
import
issu
genom
studi
cardiomyopathi
phenotyp
use
basi
comparison
one
sens
diagnosi
nonischem
idiopath
dilat
cardiomyopathi
like
repres
patient
wide
spectrum
unrel
condit
well
patient
mix
ischem
nonischem
featur
addit
analys
perform
thu
far
take
account
gene
chang
induc
treatment
regimen
furthermor
comparison
end
stage
normal
tissu
might
yield
result
difficult
interpret
potenti
less
use
clinic
howev
studi
illustr
gene
express
profil
myocardium
anoth
tissu
blood
could
studi
mean
differenti
clinic
cardiomyopathi
entiti
might
warrant
slightli
differ
pharmacolog
regimen
number
substanti
find
date
cardiovascular
genom
research
develop
commerci
avail
diagnost
test
howev
still
signific
challeng
realiz
full
potenti
genom
cardiovascular
medicin
among
hurdl
issu
surround
use
larger
number
appropri
sampl
valid
result
societ
ethic
concern
issu
enough
appropri
sampl
gene
express
studi
substanti
one
mani
level
one
level
mani
studi
includ
one
describ
use
small
number
samplesperhap
total
limit
relat
expens
assay
well
avail
suffici
sampl
number
without
larger
sampl
number
valid
analys
remain
controversi
therefor
although
data
studi
still
use
explor
hypothesi
gener
requir
substanti
clinic
applic
result
intrins
genet
socioenvironment
heterogen
within
human
popul
dictat
larger
sampl
size
perhap
order
hundr
sampl
could
make
result
clinic
applic
might
also
allow
research
fine
tune
genom
analys
detect
nuanc
diseas
state
clinic
outcom
exampl
like
distinct
gene
group
determin
atherosclerot
suscept
men
versu
women
well
racial
ethnic
group
sampl
size
limit
prevent
us
abl
studi
import
subpopul
us
multiinstitut
investig
cargo
studi
good
exampl
pool
cohort
enabl
research
gener
clinic
applic
inform
intern
number
effort
underway
develop
repositori
biolog
materi
massiv
scale
use
genom
genet
metabolom
proteom
studi
one
first
project
kind
north
health
project
sweden
biorepositori
uniqu
individu
two
recent
nation
project
unit
kingdom
biobank
biohealth
norway
plan
collect
genet
materi
clinic
inform
individu
discuss
perform
gene
express
experi
significantli
larger
scale
bring
issu
cost
larger
sampl
size
would
allow
robust
result
larger
truli
independ
train
test
set
test
clinic
util
depend
microarray
platform
use
persampl
cost
materi
reagent
microarray
rna
process
extract
label
hybrid
rang
account
cost
accru
collect
store
comprehens
longitudin
clinic
inform
certainli
develop
core
facil
help
defray
cost
still
genom
research
requir
substanti
budget
use
sampl
size
use
develop
clinic
usabl
result
number
technic
advanc
might
dramat
reduc
cost
develop
high
throughput
microarray
platform
regard
issu
sampl
number
must
make
sure
use
appropri
sampl
exampl
context
cardiomyopathi
sampl
easiest
obtain
might
come
individu
endstag
diseas
alreadi
receiv
multitud
medic
might
difficult
deciph
inform
deriv
situat
might
limit
applic
result
inform
anoth
challeng
face
genom
research
process
move
beyond
exploratori
studi
candid
gene
discoveri
toward
improv
understand
diseas
biolog
robust
statist
analysi
identifi
candid
gene
use
diagnost
test
clinic
set
howev
understand
diseas
mechan
need
truli
learn
improv
health
care
strategi
therefor
candid
gene
must
assess
function
relev
patient
diseas
process
particular
import
determin
whether
express
chang
priorit
gene
caus
role
rather
result
diseas
process
critic
further
understand
diseas
biolog
subsequ
improv
health
care
strategi
use
knock
outin
transgen
anim
vital
type
studi
addit
consid
time
expens
technic
challeng
anim
confirmatori
studi
research
need
develop
novel
straightforward
method
perhap
use
small
molecul
aptam
small
interf
rna
final
asid
scientif
challeng
number
public
polici
issu
must
address
key
issu
shift
health
care
deliveri
one
individu
health
assess
emphas
prevent
prognosi
genet
genom
inform
translat
clinic
practic
requir
modif
patient
educ
well
chang
medic
educ
clear
improv
health
outcom
reduct
health
care
cost
need
demonstr
justifi
new
potenti
expens
genet
genom
test
certainli
move
toward
abl
predict
diseas
suscept
treatment
outcom
legisl
like
necessari
protect
medic
privaci
prevent
potenti
barrier
insur
employ
cardiovascular
genom
research
still
form
stage
regard
translat
result
studi
clinic
applic
howev
examin
medic
field
demonstr
potenti
genom
medicin
cardiovascular
medicin
possibl
within
next
year
tabl
microarray
alreadi
use
oncolog
infecti
diseas
pharmacolog
help
clinician
better
riskstratifi
patient
well
predict
therapeut
respons
guid
clinic
decis
make
avail
genom
test
detect
acut
reject
cardiac
transplant
patient
repres
first
concret
exampl
start
use
gene
express
data
mainstream
clinic
enterpris
alreadi
start
gain
substanti
new
insight
common
cardiovascular
diseas
like
diagnost
test
use
genom
inform
avail
near
term
improv
predict
acut
coronari
syndrom
well
potenti
develop
malign
arrhythmia
although
signific
challeng
remain
cardiovascular
genom
medicin
promis
improv
patient
care
lower
health
care
cost
chang
way
practic
medicin
